|

Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

RECRUITINGSponsored by Xijing Hospital
Actively Recruiting
SponsorXijing Hospital
Started2011-05-01
Est. completion2026-10-01
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT01372800

Summary

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* available for 5 years of follow-up study

Exclusion Criteria:

* Death caused other than cardiovascular and cerebralvascular diseases till the study ends
* Floating Population
* Pregnancy, lactation, or child bearing women
* Tumor
* Active hepatic disease or hepatic dysfunction, or AST/ALT \> 1.5UNL
* Severe renal dysfunction(Scr \> 3 mg/dl or 264μmol/L)
* Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Conditions3

Cerebral InfarctionHeart DiseaseMyocardial Infarction

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.